Home » Drug Information » FDA Approved Drugs » 1998
Medical Areas: Ophthalmology | Family Medicine
View By:YearCompanyConditionsTherapeutic AreasDrug Names
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Isis Pharmaceuticals
Approval Status: Approved August 1998
Treatment Area: CMV Retinitis
Vitravene Injection for the local treatment of CMV retinitis in
patients with acquired immunodeficiency syndrome (AIDS) who are
intolerant of or have a contraindication to other treatment(s) for
CMV retinitis or who were insufficiently responsive to previous
treatment(s) for CMV retinitis.
The use of Vitravene does not provide treatment for systemic CMV
Vitravene injection is not a cure for CMV retinitis, and some
immunocompromised patients may continue to experience progression
of retinitis during and following treatment. Patients receiving
Vitravene should be advised to have regular ophthalmologic
follow-up examinations. Patients may also experience other
manifestations of CMV disease despite Vitravene therapy.
Abdomianl pain, anemia, diarrhea, fever, headache, infection,
nausea, pneumonia, rash, etc.